ClinicalTrials.gg
RecruitingNCT05387954CLOSE-2Updated Mar 24, 2026

PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years

A Phase 3 interventional study of Transcatheter PFO closure and Oral Anticoagulant, Direct-Acting in Cryptogenic Ischemic Stroke and Patent Foramen Ovale, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 42 sites in France. Open to participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
792
Allocation
Randomized
Ages
60 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing Factor Xa inhibitors in Ischemic Stroke — 10 open to participants now, 10 under way, 6 of them phase 3. A drug class: Factor Xa inhibitors · Ischemic Stroke.

Planned enrollment
13th of 20
792 · median 1,082
Started
2023
with 1 other
Phase 3
7 of 20
4 open now
Registered
12th of 20
by date
Lead sponsor
2 of 20
Assistance Publique - Hôpitaux de Paris

Among the 20 studies testing Factor Xa inhibitors in Ischemic Stroke, this one is the 13th largest by planned enrollment, is one of 2 that started in 2023, is one of 7 in phase 3, and was the 12th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

10 of the 20 studies testing Factor Xa inhibitors in Ischemic Stroke are open now, in 10 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About Factor Xa inhibitors

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 60 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing Factor Xa inhibitors in Ischemic Stroke, or all of them as a file.
02

Study summary

To assess whether PFO closure plus antiplatelet therapy is superior to antiplatelet therapy alone and whether oral anticoagulant therapy is superior to antiplatelet therapy to prevent stroke recurrence in patients aged 60 to 80 years with a PFO with large shunt (> 20 microbubbles) or a PFO associated with an ASA (> 10 mm), and an otherwise unexplained ischemic stroke.

Read the detailed description

The CLOSE trial (NCT00562289, NEJM 2017) has unambiguously demonstrated the superiority of patent foramen ovale (PFO) closure over antiplatelet therapy alone in patients aged up to 60 years with a PFO associated with an atrial septal aneurysm (ASA) or a large right-to-left shunt (so-called "high-risk PFO"), and an otherwise unexplained ischemic stroke. Oral anticoagulant therapy is also a logical approach assuming that PFO-related strokes are due to paradoxical embolism which implies a venous source of embolism, or to direct embolization of a thrombus formed at the atrial level. The CLOSE trial also suggested that oral anticoagulants might reduce stroke recurrence compared to aspirin.

There is accumulating evidence that presence of a PFO is significantly associated with cryptogenic stroke in patients over 60 years. Cryptogenic ischemic strokes represent about one third of all ischemic strokes in patients older than 60 years. However, the optimal therapeutic strategy in patients older than 60 years with a PFO and an otherwise unexplained ischemic stroke is unknown, because these patients were excluded from randomized trials.

The hypothesis tested in this trial is that transcatheter PFO closure plus long-term antiplatelet therapy is superior to antiplatelet therapy alone and that oral anticoagulant therapy is superior to antiplatelet therapy to prevent recurrent stroke in patients aged 60 to 80 years who have a high-risk PFO and a recent otherwise unexplained ischemic stroke.

03

Conditions studied

  • Cryptogenic Ischemic Stroke
  • Patent Foramen Ovale

Keywords

  • Ischemic stroke
  • Cryptogenic stroke
  • Patent foramen ovale
  • Atrial septal aneurysm
  • Transcatheter PFO closure
  • Oral anticoagulants
  • Antiplatelet therapy
  • Randomized clinical tria
04

Who can participate

Ages eligible
60 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Man or woman aged 60 to 80 years.
  • Recent (≤ 6 months) ischemic stroke confirmed by cerebral imaging regardless of symptom duration.
  • Absence of a more probable cause of stroke than PFO after a standardized etiological work-up (see addenda).
  • Presence of a PFO with at least 1 of the 2 following characteristics:

    • PFO with large shunt (> 20 microbubbles) appearing in the left atrium during at least one of the 3 cardiac cycles after complete opacification of the right atrium, detected either spontaneously or during provocative manoeuvers, on contrast transthoracic (TTE) or transoesophageal (TOE) echocardiography. The diagnosis of PFO by contrast TEE must be confirmed by contrast TOE showing a right-to-left passage of the contrast material across the PFO.
    • PFO associated with an ASA on transoesophageal echocardiography: excursion >10 mm
  • Affiliation to a French Health Insurance system. .

Exclusion criteria

Exclusion Criteria:

  • \< 4 years.
  • to both experimental treatments (PFO closure, oral anticoagulant therapy) or to the reference treatment (antiplatelet therapy) (see paragraph 20.5).
  • Indication to long-term anticoagulant therapy.
  • mRS > 3.
  • Presence of other medical conditions that would lead to inability to complete the study or interfere with the assessment of outcomes.
  • Previous surgical or transcatheter treatment of PFO or ASA. Expected impossible follow-up or poor compliance.
  • PFO associated with an atrial septal defect (ASD) requiring closure (significant shunt with impact on the right cavities, elevation of pulmonary pressures or QP/QS>2)
  • Patient unable to understand the form. Patient under tutorship, curatorship, or legal protection.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
792 participants (estimated)

Study arms

  • Active comparator
    Antiplatelet therapy

    Aspirin OR clopidogrel

    Drug: Antiplatelet therapy

  • Experimental
    Oral anticoagulants, Direct-Acting

    Apixaban (5mg twice a day) OR Dabigatran (150 mg twice a day) OR Rivaroxaban (20 mg once a day)

    Drug: Oral Anticoagulant, Direct-Acting

  • Experimental
    PFO closure

    PFO closure followed by dual antiplatelet therapy (aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then by single antiplatelet therapy by aspirin or clopidogrel

    Procedure: Transcatheter PFO closure · Drug: Antiplatelet therapy

Interventions

  • ProcedureTranscatheter PFO closure

    PFO closure followed by dual antiplatelet therapy (aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then by single antiplatelet therapy by aspirin or clopidogrel until the end of the study.

    Also known as: •Each device for PFO closure must have the CE mark, •and be approved by the Interventional Cardiology Committee

  • DrugFactor Xa inhibitorsStudies of Factor Xa inhibitorsFactor Xa inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Apixaban (5mg twice a day) OR Dabigatran (150 mg twice a day) OR Rivaroxaban (20 mg once a day)

  • DrugAntiplatelet therapy

    Patients randomized to this arm will receive antiplatelet therapy throughout the study : aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then single antiplatelet therapy by aspirin or clopidogrel

06

What researchers measure

Primary outcomes

  1. Time to recurrent stroke (ischemic or hemorrhagic fatal or non-fatal)

    Stroke: sudden onset of focal neurological symptoms related to a disturbance of the cerebral circulation. Ischemic stroke : at least one of the following criteria: * Sudden onset of focal neurological symptoms with the presence of cerebral infarction in the appropriate territory on brain imaging (CT or MRI), regardless of the duration of symptoms (less than or more than 24 hours). * Sudden onset of focal neurological symptoms lasting more than 24 hours, with no apparent cause other than cerebral ischemia. Intracerebral hemorrhage: sudden onset of focal neurological symptoms with the presence of cerebral hemorrhage in the appropriate territory on brain imaging (CT or MRI), regardless of the duration of symptoms (less than or more than 24 hours) and regardless of the cause of the hemorrhage (spontaneous or secondary to trauma, tumour or another cause). Unknown type of stroke : the type of stroke cannot be determined with certainty and the symptoms last more than 24 hours.

    Time frame: From date of randomization until the date of first recurrent stroke, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included)

Secondary outcomes

  1. Time to disabling stroke

    mRS score greater than or equal to 3, with an increase of at least 2 points compared to the last mRS score before the stroke.

    Time frame: From date of randomization until the date of first recurrent disabling stroke, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included)

  2. Time to ischemic stroke

    At least one of the following criteria: * Sudden onset of focal neurological symptoms with the presence of cerebral infarction in the appropriate territory on brain imaging (CT or MRI), regardless of the duration of symptoms (less than or more than 24 hours). * Sudden onset of focal neurological symptoms lasting more than 24 hours, with no apparent cause other than cerebral ischemia.

    Time frame: From date of randomization until the date of first recurrent ischemic stroke, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included)

  3. Time to ischemic stroke or systemic embolism

    Clinical features related to embolism usually affecting a limb, mesenteric, splenic, or renal artery. The diagnosis of embolism must be confirmed by appropriate investigations.

    Time frame: From date of randomization until the date of first recurrent ischemic stroke or systemic embolism, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included)

  4. Time to transient ischemic attack,

    Sudden onset of neurological symptoms, presumed to be ischemic, resolving in less than 24 hours, clearly attributable to focal involvement of the central nervous system (or of the eye) with no signs of a corresponding recent cerebral infarction on brain imaging. The diagnosis of TIA will be confirmed by a neurologist, considering clinical data and brain imaging (MRI with diffusion sequence is recommended).

    Time frame: From date of randomization until the date of first transient ischemic attack, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included)

  5. Time to vascular death

    * death related to a cardiac or vascular cause. * death due to hemorrhage. * death due to pulmonary embolism. * sudden death: death occurring in less than 24 hours, unexpectedly in a subject in apparent good health and whose condition was stable or was improving. * death with no documented non-vascular cause. * fatal stroke: death occurring within 30 days of a stroke (ischemic or hemorrhagic).

    Time frame: From date of randomization until the date of vascular death, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included)

  6. Time to all-cause mortality

    Vascular (see definition) or nonvascular death: death due to a documented non-vascular cause (infection, cancer, accident, suicide, etc.).

    Time frame: From date of randomization until the date of death, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included)

  7. Quality of life score

    Measured by using the European Quality Of Life (EQ-5D) auto-questionnaire. The digits for the five dimensions are combined into a 5-digit number that describes the patient's health state. The visual analogue scale (VAS) records the patient's self-rated health on a vertical axis from 0 (worst health) to 100 (best health)

    Time frame: Every 6 months after randomization or up to 4 years (for the last patient included) to up to 8 years (for the first patient included)]

  8. Time to fatal, life-threatening or major hemorrhage, including intracerebral and Intracranial hemorrhage

    Life-threatening * Fatal hemorrhage. * Drop in hemoglobin by ≥ 5 g/dL (or drop in hematocrit by 15% or more in absolute value) * Symptomatic intracranial hemorrhage (confirmed by appropriate investigations, classified as cerebral hemorrhage, subarachnoid hemorrhage and subdural hematoma). * Transfusion ≥ 4 units of packed cells (or equivalent of whole blood)\*. Major * Transfusion ≤ 3 units of packed cells (or equivalent of whole blood)\*. * Requiring hospitalization (or prolonging hospitalization). * Requiring surgical treatment. * Intraocular hemorrhage with significant loss of vision. * Other hemorrhage responsible for significant disability according to the investigator.

    Time frame: From date of randomization until the date of first fatal,life-threatening or major hemorrhage,including intracerebral and Intracranial hemorrhage,assessed from up to 4 years(for the last patient included) to up to 8 years(for the first patient included)

  9. Proportion of success of device implantation, of the procedure and of PFO closure,

    * Success of device implantation: deployment of the device in the appropriate place and removal of the placement system. * Success of the procedure: successful implantation with no complications before the patient's discharge. * Success of PFO closure: success of the procedure with no residual shunt or minimal residual shunt on echocardiography performed 6 months after the procedure.

    Time frame: 6 months after PFO closure

  10. Time to ischemic stroke recurrence according to the presence of a residual shunt

    From control echocardiography after PFO closure to the end of the patient's follow-up

    Time frame: From date of PFO closure until the date of first ischemic stroke recurrence, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included), according to the presence of residual shunt]

  11. Time to new-onset atrial fibrillation

    Atrial fibrillation lasting at least 30 seconds

    Time frame: From date of randomization until the date of new-onset atrial fibrillation, assessed from up to 4 years (for the last patient included) to up to 8 years (for the first patient included)]

  12. Proportion of fatal, life-threatening or major procedure- or device-related complications

    Life-threatening * Cardiac perforation with tamponade requiring emergency drainage. * Cerebral air embolism responsible for acute neurological disorders * Embolization of the device. * Life-threatening hematoma at the puncture site or retroperitoneal. * Complications of general anesthesia or TOE requiring intensive care and/or surgical operation. Major * Hemorrhage at the puncture site or retroperitoneal requiring transfusion or surgery. * Arteriovenous fistula, pseudoaneurysm requiring surgery. * Peripheral nerve lesion with disabling neurological deficit persisting \> 1 month. * Cardiac arrhythmias (particularly AF) during catheterization or post-procedure requiring treatment \>= 1 month. * Infective endocarditis. * Asymptomatic late thrombosis of the device. * Any device-related complication requiring surgery. * Any other complication related to the transcatheter treatment or anesthesia, considered to be major by the investigator.

    Time frame: Within 4 weeks following the procedure (PFO closure)

  13. Costs

    Costs will be estimated from the viewpoint of the healthcare system (hospital admission, transportation, study interventions, emergency room visit without admission,consultations,imaging)

    Time frame: Within 48 months after randomization

  14. Incremental cost-utility ratio at 4 years (ICUR)

    The incremental cost-utility ratio (ICUR) will be calculated as difference in costs (between groups)/difference in QALYs (Quality-Adjusted Life Year) between groups. The QALYs will be constructed with the EuroQoL-5D (EQ-5D) questionnaire and value sets

    Time frame: Within 48 months after randomization

07

Study locations

42 of 42 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data (IPD) that underlie results in publication could be shared. IPD detailed in the protocol of a planned metaanalysis could be shared

Supporting information: Study protocol, Informed consent form

Time frame: Two years after the last publication

Access criteria: Data sharing must be accepted by the sponsor and the PI based on a scientific project and scientific involvement of the PI team. Collaboration will be fostered. Data sharing must respect the agreements made with funders. Teams wishing obtain IPD must meet the sponsor and PI team to present scientific (and commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasability and financial support will be discussed before mandatory contractual agreement. Processing of shared data must comply with European General Data Protection Regulation (GDPR).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jul 2031, 96 months after the start.

Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 96 months is above that.

Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2022
First posted
May 24, 2022
StartActual
Jul 7, 2023
Primary completionEst.
Jul 7, 2031
CompletionEst.
Jul 7, 2031
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05387954
Collaborators
Ministry of Health, France, W.L.Gore & Associates, Abbott, Occlutech International AB, Centre Hospitalier St Anne
Responsible party
Sponsor
First posted
May 24, 2022
Start date
Jul 7, 2023
Primary completion
Jul 7, 2031 (estimated)
Completion
Jul 7, 2031 (estimated)
Last update
Mar 24, 2026

Study contacts

Carla Vandenabele
Contact
carla.vandenabele@aphp.fr
+331 44 84 57 27
Malha Berrah
Contact
malha.berrah@aphp.fr
Jean-Louis Mas, MD
principal investigator · GHU Psychiatrie et Neurosciences Paris
Gilles Chatellier, MD
study director · Hôpital Européen Georges-Pompidou

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Factor Xa inhibitors

Start the discussion